Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $16.24
Previous CloseN/A
Volume369.36K
Average Volume (3M)993.62K
Market Cap
$123.50M
Enterprise Value$134.90M
Total Cash (Recent Filing)-$7.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 20, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding70,568,756
10 Day Avg. Volume1,050,820
30 Day Avg. Volume993,620
Standard Deviation0.34
R-Squared0.01
Alpha-0.00857
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.99
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$7.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Nkarta News
PremiumCompany Announcements
Nkarta, Inc. Reports Q3 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient has been dosed in the Ntrust-1 study for NKX019, marking a significant milestone in the treatment of lupus nephritis.
Development StrategyThere is an appreciation of Nkarta’s development strategy and clinical rationale for lead program NKX019 in lupus nephritis and autoimmune diseases.
Bears Say
Strategic DecisionsNkarta decided not to further invest in another CD19-directed cell therapy for the competitive B-cell lymphoma market, indicating a strategic shift away from these indications.
---
Ownership Overview
21.70% Insiders
10.75% Mutual Funds
0.02% Other Institutional Investors
59.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.70 and its highest was $16.24 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $123.50M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Mar 20, 2025 which is in 17 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Nov 07, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.368 by -$0.022.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.41.
How many shares outstanding does Nkarta have?
Nkarta has 70,568,756 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.368. Following the earnings report the stock price went down -2.446%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
---
Nkarta Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (300.00% Upside)
$7.00 (300.00% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 125.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.90%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
31.09%
Trailing 12-Months
Company Description
Nkarta
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
---
NKTX Stock 12 Month Forecast
Average Price Target
$7.00
▲(300.00% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering NKTX
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-12.04%
reiterated a buy rating 4 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -12.04% per trade.
---